HEK293-CLDN18.2 Cells
USUSD$1,900.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
一般資訊
| 說明 | Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. HEK293-CLDN18.2 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human claudin 18 isoform 2 (CLDN18.2), a tight junction-associated transmembrane protein belonging to the claudin family. CLDN18.2 is a gastric lineage-specific isoform normally restricted to differentiated gastric mucosal epithelial cells, where its extracellular domains are largely inaccessible under physiological conditions. In malignant transformation, disruption of epithelial polarity and tight junction architecture exposes CLDN18.2 on the tumor cell surface, leading to its overexpression and accessibility in several cancers, including gastric adenocarcinoma, gastroesophageal junction cancer, pancreatic cancer, and other gastrointestinal malignancies. Because of its highly restricted normal tissue distribution and tumor-associated exposure, CLDN18.2 has emerged as a clinically important therapeutic target in oncology. HEK293-CLDN18.2 cells are widely used for development and characterization of CLDN18.2-targeted therapeutics, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, CAR-T and CAR-NK cell therapies, and targeted imaging agents. The stable recombinant expression system enables quantitative analysis of antigen binding affinity, epitope specificity, receptor density, internalization kinetics, and target-dependent cytotoxicity. These cells are also commonly employed in flow cytometry assays, reporter assays, antibody screening workflows, and immune effector functional studies designed to evaluate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Because HEK293 cells support robust recombinant membrane protein expression and efficient propagation, they provide a reliable platform for standardized CLDN18.2 assay development and therapeutic validation. |
|---|---|
| 生物體 | Human |
| 組織 | Fetal Kidney |
| 疾病 | Transformed/immortalized; non-tumorigenic (HEK293 background) |
| 應用 | CLDN18.2-targeted antibody and ADC development; CAR-T/CAR-NK cell therapy; ADCC/CDC assays; flow cytometry; gastric/GEJ/pancreatic cancer therapeutics |
特徵
| 年齡 | Fetus |
|---|---|
| 性別 | Female |
| 形態學 | Epithelial-like |
| 細胞類型 | Epithelial cells |
| 生長特性 | Monolayer, adherent |
監管數據
| 引用 | HEK293-CLDN18.2 (Cytion catalog number 305986) |
|---|---|
| 生物安全等級 | 1 |
| NCBI_TaxID | 9606 |
| Cellosaurus 編號 | CVCL_E5J2 |
| 轉基因狀態 | GMO-S1: This HEK293 cell line contains a CLDN18.2 expression construct for tight junction antigen studies and targeted cancer therapy development. This classification applies only within Germany and may differ elsewhere. |
生物分子資料
| 表面抗原 | CLDN18.2 |
|---|---|
| 受體的表達 | CDLN18.2 |
處理方式
| 培養基 | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| 營養補充品 | Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. |
| 解離試劑 | Trypsin-EDTA |
| 倍增時間 | approx. 24-36 hours |
| 傳代培養 | For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO2, and change the medium every 2-3 days. |
| 拆股比例 | 1 to 5 |
| 播種密度 | 2 to 4 x 104 cells/cm2 |
| 流體更新 | 2 to 3 times per week |
| 解凍後的恢復 | After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere (for adherent cultures) for at least 24 hours. |
| 冷凍培養基 | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| 細胞解凍與培養 |
|
| 培養環境 | 37°C, 5% CO2, humidified atmosphere. |
| 運送條款 | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| 儲存條件 | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
品質控制與分子分析
| 不孕症 | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|